Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma

Trial Profile

Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 18 Aug 2015 According to an ALK-Abello media release, the New Drug Application submitted by its partner, Torii, to the Japanese Ministry of Health, Labour and Welfare has been accepted for review.
    • 02 Sep 2014 Based on results of this trial and the second pivotal trial, Torii Pharmaceuticals is expected to submit a registration application in Japan within 6 months, according to an ALK-Abello media release.
    • 16 Jun 2014 Primary endpoint 'Risk of moderate to severe asthma exacerbations' has not been met according to the ALK-Abello media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top